Literature DB >> 1277218

Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.

G Peter, T Wagner, H J Hohorst.   

Abstract

4-Hydroperoxycyclophosphamide was obtained in approximately 20% yield by ozonization of cyclophosphamide in acetone/water at 0 degrees C. It was reduced to 4-hydroxycyclophosphamide, which was treated with several mercaptans to yield compounds of the type 4-(S-R)-mercapto-cyclophosphamide. In the solid state these compounds are stable at room temperature; in aqueous solution they are hydrolyzed to 4-hydroxycyclophosphamide or its tautomer, aldophosphamide. One of the 4-(S-R)-mercapto-cyclophosphamide compounds was tested biologically in vitro against Yoshida ascites tumor cells and showed the same cytotoxic activity as 4-hydroxycyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277218

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

1.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

2.  Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.

Authors:  L Bielicki; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

3.  Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.

Authors:  U Niemeyer; J Engel; G Scheffler; K Molge; D Sauerbier; W Weigert
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  The influence of the protector thiol L-cystein on the toxic and therapeutic responses of stabilized "activated" cyclophosphamide (4-(S-ethanol)-sulfido-cyclophosphamide).

Authors:  G Voelcker; P Laber; H Rockinger; C Wientzek; H J Hohorst
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

6.  [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Authors:  T Wagner; D Heydrich; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

7.  Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

Authors:  G Peter; H J Hohorst
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Does acrolein contribute to the cytotoxicity of cyclophosphamide?

Authors:  E Wrabetz; G Peter; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

Review 9.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

10.  [Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].

Authors:  G Voelcker; R Haeglsperger; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.